

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human IL-22 R $\alpha$ 1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) IL-10, rhIL-22BP or rhIL-20 R $\alpha$ is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 305405
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human IL-22 R $\alpha$ 1 Pro18-Thr228 Accession # Q8N6P7
<b>Conjugate</b>	Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm
<b>Formulation</b>	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Flow Cytometry</b>	10 $\mu$ L/10 <sup>6</sup> cells	See Below

## DATA



## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, 2 to 8 °C as supplied.</li> </ul>

**BACKGROUND**

IL-22 receptor, also known as IL-22 R $\alpha$ 1 and CRF2-9, is an approximately 65 kDa transmembrane glycoprotein in the type II cytokine receptor family (CRF). IL-22 R $\alpha$ 1 contains a 211 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, and a 323 aa cytoplasmic domain. IL-22 R $\alpha$ 1 associates with either IL-10 R $\beta$  or IL-20 R $\beta$  to form receptor complexes with distinct ligand selectivities. IL-10 R $\beta$  is a shared subunit of the IL-10, -22, -26, -28, and -29 receptors, while IL-20 R $\beta$  is a shared subunit of the IL-19, -20, -22R and -24 receptors (1). IL-22 R $\alpha$ 1/IL-10 R $\beta$  is an IL-22 responsive receptor (2, 3), and IL-22 R $\alpha$ 1/IL-20 R $\beta$  is an IL-20 or IL-24 responsive receptor (4, 5). IL-22 R $\alpha$ 1 contains cytoplasmic motifs for interactions with signal transduction molecules, but formation of ternary complexes with IL-10 R $\beta$  or IL-20 R $\beta$  and the respective ligands is required for signal transduction (2, 6). IL-22BP functions as a competitive antagonist by binding IL-22 and preventing its association with IL-22 R $\alpha$ 1 (7, 9). Even though it is a receptor for interleukins, IL-22 R $\alpha$ 1 is not expressed on hematopoietic cells (6, 10, 11). Instead, IL-22 R $\alpha$ 1 expression is restricted to epithelial and stromal cells (6, 10–13). IL-22 R $\alpha$ 1 signaling promotes innate immune responses and wound healing at sites of infection and inflammation. This includes upregulation of antimicrobial, acute phase, proinflammatory, and extracellular matrix proteins as well as proteases (3, 11, 13, 14). IL-22 R $\alpha$ 1 signaling also promotes downregulation of proteins involved in keratinocyte differentiation (3, 14). Within the ECD, human IL-22 R $\alpha$ 1 shares 78%, 76%, and 83% aa sequence identity with mouse, rat, and canine IL-22 R, respectively. It shares 22%–25% aa sequence identity with the ECDs of other class II receptors IL-10 R, IL-20 R, and IL-28 R.

**References:**

1. Langer, J.A. *et al.* (2004) Cytokine Growth Factor Rev. **15**:33.
2. Xie, M.-H. *et al.* (2000) J. Biol. Chem. **275**:31335.
3. Boniface, K. *et al.* (2005) J. Immunol. **174**:3695.
4. Dumoutier, L. *et al.* (2001) J. Immunol. **167**:3545.
5. Wang, M. *et al.* (2002) J. Biol. Chem. **277**:7341.
6. Kotenko, S.V. *et al.* (2001) J. Biol. Chem. **276**:2725.
7. Li, J. *et al.* (2004) Int. Immunopharmacol. **4**:693.
8. Logsdon, N.J. *et al.* (2002) J. Interferon Cytokine Res. **22**:1099.
9. Kotenko, S.V. *et al.* (2001) J. Immunol. **166**:7096.
10. Nagalakshmi, M.L. *et al.* (2004) Int. Immunopharmacol. **4**:577.
11. Nagalakshmi, M.L. *et al.* (2004) Int. Immunopharmacol. **4**:679.
12. Aggarwal, S. *et al.* (2001) J. Interferon Cytokine Res. **21**:1047.
13. Wolk, K. *et al.* (2004) Immunity **21**:241.
14. Wolk, K. *et al.* (2006) Eur. J. Immunol. **36**:1309.